View More Recent Stories

Apr 29, 2015 08:00AM Portola Pharmaceuticals to Announce First Quarter 2015 Financial Results and Host Conference Call on Wednesday, May 6
Apr 29, 2015 08:00AM Portola Pharmaceuticals to Announce First Quarter 2015 Financial Results and Host Conference Call on Wednesday, May 6
Apr 8, 2015 08:00AM Portola Pharmaceuticals Announces New Topline Data From Phase 3 ANNEXA-A(TM) Trial Part 2: Breakthrough Designated Andexanet Alfa Successfully Meets Primary Endpoint for Prolonged Reversal of Factor X
Feb 26, 2015 08:00AM Portola Pharmaceuticals Receives FDA Orphan Drug Designation for Andexanet Alfa, Its Breakthrough-Designated Factor Xa Inhibitor Antidote
Feb 25, 2015 04:00PM Portola Pharmaceuticals to Present at the Cowen and Company 35th Annual Health Care Conference
Feb 24, 2015 04:00PM Portola Pharmaceuticals to Announce Fourth Quarter and Year End 2014 Financial Results and Host Conference Call on Monday, March 2
Feb 9, 2015 04:00PM Portola Pharmaceuticals Appoints Two Biotechnology Industry Veterans, Laura Brege and Dr. Dennis Fenton, to Board of Directors
Feb 5, 2015 04:06PM Portola's Factor Xa Inhibitor Betrixaban Successfully Passes Futility Analysis in Phase 3 APEX Study; Trial Continues as Planned and Remains on Track for Enrollment Completion by Year-End
Jan 26, 2015 11:52AM Portola Pharmaceuticals Announces Dr. Robert Califf Retires From the Board of Directors to Accept Position as Deputy Commissioner for Medical Products and Tobacco at the Food and Drug Administration (
Jan 9, 2015 08:00AM Portola Announces Phase 3 ANNEXA-R Study of Andexanet Alfa and Factor Xa Inhibitor XARELTO(R) (rivaroxaban) Met Primary Endpoint With High Statistical Significance
Jan 6, 2015 04:00PM Portola Pharmaceuticals Announces Webcast of Corporate Presentation on January 12, 2015
Nov 10, 2014 04:01PM Portola Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update
Nov 6, 2014 09:00AM Portola Pharmaceuticals Announces Upcoming Presentations at the American Society of Hematology 2014 Annual Meeting
Nov 6, 2014 08:00AM Portola Pharmaceuticals to Present at the Credit Suisse 2014 Healthcare Conference
Oct 16, 2014 04:05PM Portola Pharmaceuticals Announces Commercial Supply Agreement for Andexanet Alfa With Lonza
Oct 2, 2014 09:28AM Pre-Open Stock Movers 10/02: (ESPR) (RLD) (TSLA) Higher; (CREE) (WILN) (GPRO) Lower (more...)
Aug 6, 2014 04:00PM Portola Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update
Jul 7, 2014 02:10PM Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Daiichi Sankyo for Phase 3 Studies of Factor Xa Inhibitor Antidote, Andexanet Alfa, and Edoxaban
Jun 12, 2014 04:00PM Portola Pharmaceuticals to Present at the 2014 Wells Fargo Securities Healthcare Conference
Jun 11, 2014 08:00AM Portola Pharmaceuticals Announces Positive Phase 2 Data With FDA-Designated Breakthrough Therapy Andexanet Alfa and Enoxaparin
May 14, 2014 05:00PM Portola Pharmaceuticals Announces Two Presentations of Data on Cerdulatinib, an Oral Dual Syk/JAK Inhibitor, at 2014 ASCO Annual Meeting
May 12, 2014 04:02PM Portola Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
May 5, 2014 08:00AM Portola Pharmaceuticals to Announce First Quarter 2014 Financial Results and Host Conference Call on Monday, May 12, 2014
Mar 19, 2014 08:00AM Portola Pharmaceuticals Initiates Phase 3 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, Under Accelerated Approval Pathway
Mar 18, 2014 08:00AM Portola Pharmaceuticals Appoints John H. Johnson to Board of Directors
Feb 27, 2014 04:01PM Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate Update
Feb 24, 2014 08:00AM Portola Pharmaceuticals to Present at the Cowen and Company 34th Annual Health Care Conference
Feb 20, 2014 08:00AM Portola Pharmaceuticals to Announce Fourth Quarter and Year End 2013 Financial Results and Host Conference Call on Thursday, February 27, 2014
View More Recent Stories